Philippe Moreau1, S Vincent Rajkumar2. Show Affiliations » 1. Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. 2. Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: rajkumar.vincent@mayo.edu.
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, Humanized/therapeutic useAntineoplastic Agents/therapeutic useBoron Compounds/therapeutic useBortezomib/therapeutic useBridged Bicyclo Compounds, HeterocyclicClinical Trials as TopicDrug ApprovalDrug DiscoveryGlycine/analogs & derivativesGlycine/therapeutic useHumansLactones/therapeutic useLenalidomideMultiple Myeloma/drug therapyOligopeptides/therapeutic usePractice Guidelines as TopicPyridinium CompoundsPyrroles/therapeutic useThalidomide/analogs & derivativesThalidomide/therapeutic use
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBoron CompoundsBridged Bicyclo Compounds, HeterocyclicLactonesONX 0912OligopeptidesPyridinium CompoundsPyrroleselotuzumabdinaciclibdaratumumabThalidomideBortezomibmarizomibixazomibLenalidomideGlycine
Year: 2016 PMID： 27411865 DOI： 10.1016/S0140-6736(16)30954-0
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321